ema prac naion semaglutide june 2025 The use of in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for diabetes that belong to Ischemic Optic Neuropathy Treatment Market

The industry isnt just facing changing preferencesits facing changing physiology

[1] [2] Proper timing of these medications is crucial

G., Gannon, J., & Rich, P

One known side effect of semaglutide is dry mouth, where your body produces less saliva

The STEP trials (Semaglutide Treatment Effect in People with Obesity) showed that patients lost 1522% of body weight over 68 weeks on semaglutide, with an average calorie deficit of 500600 calories dailyachieved primarily through appetite suppression rather than willpower

It is therefore clear that currently available GLP-1RAs, mimicking on the peripheral action of GLP-1 (7-36) NH2 , not only ignore the yet unknown physiology of GLP-1 (9-36) NH2 or its metabolites, but they also fail to address the tissue specific physiology of GLP-1 (7-36) NH2 , while pushing to supra-physiological limits the endocrine GLP-1 receptor axis, likely explaining the reported side-effects and only partial success in the treatment of T2D